CTXR Citius Pharmaceuticals Inc
Company Analysis
Latest News
🟢 Citius Pharmaceuticals is trading 12.11% up today
Citius Pharmaceuticals is trading 12.11% up at $0.65 after rebounding from several volatile sessions. - Shares declined 25.62% on August 17 and fell 4.13% on...
🟢 Citius Pharmaceuticals is trading 6.95% up today with Nasdaq and S&P 500 higher
Citius Pharmaceuticals is trading at $0.62 (+6.95%) as broader markets gain. - The stock is rebounding after several volatile sessions, including a 25.62%...
🔴 Citius Pharmaceuticals is trading 5% down today as investors weigh Nasdaq’s $1 minimum-bid requirement
Citius Pharmaceuticals is trading 5% down at $0.57 as investors weigh Nasdaq’s extension requiring the company to regain the $1.00 minimum bid price by...
Citius Pharma Granted Nasdaq Extension to Meet Minimum Bid Price Requirement
Citius Pharmaceuticals, Inc. (CTXR) announced it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum $1.00 bid price...
🔴 Citius Pharmaceuticals is trading 5.9% down today amid broader market risk-off pressure
Citius Pharmaceuticals is trading at $0.60, down 5.9% (-5.85%) amid broader risk-off trading, with no major company-specific announcement identified for August...
🟢 Citius Pharmaceuticals is trading 11.9% up today as healthcare stocks rally
Citius Pharmaceuticals is trading 11.9% up at $0.64, outperforming the broader market as healthcare stocks rally, with added support from a rebound after the...
🟢 Citius Pharmaceuticals is trading 5.71% up in pre-market after prior session’s sharp decline
Citius Pharmaceuticals is trading 5.71% up at $0.59, appearing to make a tentative recovery after the prior session’s sharp decline. - It fell 25.62% to $0.56...
Citius Pharma's Cancer Drug Is Gaining Traction — But Can It Outrun the Cash Clock?
Shares of Citius Pharmaceuticals (CTXR) tumbled 11.3% to $0.67 after the company's fiscal third-quarter report on August 14 revealed a painful mismatch: its...
🔴 Citius Pharmaceuticals is trading 11.33% down in pre-market after revenue shortfall and limited cash runway
Citius Pharmaceuticals is trading 11.33% down now at $0.67 after its August 14, 2026 fiscal third-quarter report highlighted a revenue shortfall and limited...
Citius Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 18, 2026
For the fiscal quarter ending June 30, 2026, Citius Pharmaceuticals is expected to report a consensus EPS of -$0.36 on revenue of $5.46 million, as the stock...
🔴 Citius Pharmaceuticals is trading 11.86% down in after-hours trading after citing substantial additional funding needs
Citius Pharmaceuticals is trading at $0.67 (-11.86%) in after-hours trading after reporting an $8.9 million quarterly net loss and substantial funding...
🔴 Citius Pharmaceuticals is trading 6.03% down in after-hours trading after announcing fiscal third-quarter 2026 results with a net loss per share of $0.34, which was narrower than analyst estimates.
Citius Pharmaceuticals is trading 6.03% down at $0.71 in after-hours trading after releasing fiscal third-quarter 2026 results on August 14, 2026. The company...
Citius Pharmaceuticals third quarter 2026 revenue reached $1.5M as LYMPHIR commercial launch builds momentum
Citius Pharmaceuticals reported its third quarter 2026 results, highlighted by the continued commercial ramp of LYMPHIR, which generated $1.5 million in...
🟢 Citius Pharmaceuticals is trading 5.73% up today — No clear company-specific catalyst identified
Citius Pharmaceuticals is trading 5.73% up at $0.78, with no clear company-specific announcement or reliable report directly explaining the August 14, 2026...
🔴 Citius Pharmaceuticals is trading 5.22% down today as immediate catalyst remains unclear
Citius Pharmaceuticals is trading at $0.73 (-5.22%) after opening-market weakness on August 13, 2026; the immediate catalyst is unclear. - No fresh...
🟢 Citius Pharmaceuticals is trading 5.4% up today amid broader market gains; no direct catalyst identified
Citius Pharmaceuticals is trading 5.4% up at $0.76, with no fresh company-specific announcement identified to explain the advance. - The move extends from the...
🔴 Citius Pharmaceuticals is trading 5.22% down today — no fresh company-specific explanation identified
Citius Pharmaceuticals is trading 5.22% down at $0.68, with no fresh company-specific announcement identified to explain the August 12, 2026 decline. - The...
🟢 Citius Pharmaceuticals is trading 5% up today as LYMPHIR adoption strengthens
Citius Pharmaceuticals is trading at $0.71 (+5.20%) as stronger LYMPHIR commercial adoption drives the move. • New ordering institutions increased 78% quarter...
🟢 Citius Pharmaceuticals is trading 6.5% up in pre-market on 78% growth in new LYMPHIR ordering sites
Citius Pharmaceuticals is trading 6.52% up at $0.73 after updates showed stronger LYMPHIR commercial adoption and expanding institutional demand. - New...
Citius Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Citius Pharmaceuticals is expected to report a Q2 2026 consensus loss of $0.36 per share on revenue of approximately $12.52 million, while the stock currently...